FORMULATION AND EVALUATION OF LIQUISOLID COMPACT OF CANDESARTAN WITH β-CYCLODEXTRIN

The liquisolid technique was chosen to enhance the dissolution properties of Candesartan. The study aimed to investigate the complexation of Candesartan with β-cyclodextrin in improving the dissolution profile of Candesartan. Candesartan is a BCS class-II drug. The inclusion complexes were formed by physical mixing (1:1 ratio). Liquisolid compacts were prepared by using, propylene glycol, tween 20 as the nonvolatile liquid vehicles. Avicel pH 102 was used as the carrier and aerosil 200 as a coating material and sodium starch glycolate as the disintegrant respectively. The pre-formulation studies like melting point, flow properties of Candesartan were compiled with IP standards. The FT-IR spectra revealed that there was no interaction between drug and excipient. Liquisolid compact (LS8) was showing the best release. Stability studies showed that there were no significant changes in physical and chemical properties of a tablet of formulation LS8 after 3 months. This research work has produced encouraging results in terms of increasing the in-vitro dissolution of poorly soluble drugs such as Candesartan using liquisolid technology. The technique is simple and effective can also be extended to other poorly soluble drugs.